2022
Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
Tuan J, Kayani J, Fisher A, Kotansky B, Dembry L, Datta R. Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e83. PMID: 36483361, PMCID: PMC9726471, DOI: 10.1017/ash.2022.229.Peer-Reviewed Original ResearchDalbavancin administrationOutpatient parenteral antimicrobial therapyDose of dalbavancinMedian antibiotic durationSoft tissue infectionsParenteral antimicrobial therapyAntibiotic durationDeveloped hepatotoxicityClinical cureSeptic arthritisClinical outcomesAntimicrobial therapyPatientsAdministrationDaysEndocarditisArthritisBacteremiaOsteomyelitisHepatotoxicityTherapyDalbavancinInfectionDose
2019
Antimicrobial therapy for asymptomatic bacteriuria or candiduria in advanced cancer patients transitioning to comfort measures
Datta R, Wang T, Zhu M, Dembry LM, Han L, Allore H, Quagliarello V, Juthani-Mehta M. Antimicrobial therapy for asymptomatic bacteriuria or candiduria in advanced cancer patients transitioning to comfort measures. Infection Control And Hospital Epidemiology 2019, 40: 470-472. PMID: 30821230, PMCID: PMC6482377, DOI: 10.1017/ice.2019.22.Peer-Reviewed Original ResearchConceptsUrinary tract infectionIncidence rate ratiosAdvanced cancer patientsAsymptomatic bacteriuriaCancer patientsAntimicrobial therapySymptomatic urinary tract infectionPotential urinary tract infectionTract infectionsInappropriate therapyAntimicrobial daysComfort measuresBacteriuriaCandiduriaCFU/mLPatientsTherapyRate ratioMLInfection
2015
Focal renal infections and papillary necrosis
Banach D, Dembry L. Focal renal infections and papillary necrosis. 2015, 434-438. DOI: 10.1017/cbo9781139855952.076.Chapters
1997
RENAL AND PERIRENAL ABSCESSES
Dembry LM, Andriole VT. RENAL AND PERIRENAL ABSCESSES. Infectious Disease Clinics Of North America 1997, 11: 663-680. PMID: 9378929, DOI: 10.1016/s0891-5520(05)70379-2.Peer-Reviewed Original ResearchConceptsRenal cortical abscessCortical abscessesIntrarenal abscessAntibiotic therapyAcute multifocal bacterial nephritisAcute focal bacterial nephritisFocal bacterial nephritisRenal corticomedullaryPerirenal abscessRenal abscessSerious prognosisXanthogranulomatous pyelonephritisClinical presentationElusive diagnosisNegative uropathogensAntistaphylococcal therapyComplete nephrectomyAbscessRadiographic studiesRadiologic techniquesTherapyNephritisDiagnosisPyelonephritisNephrectomy
1995
Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis.
Vazquez J, Lundstrom T, Dembry L, Chandrasekar P, Boikov D, Parri M, Zervos M. Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis. Bone Marrow Transplantation 1995, 16: 849-53. PMID: 8750282.Peer-Reviewed Original ResearchConceptsHigh-dose amphotericin BMinimum inhibitory concentration (MIC) rangeSustained neutropeniaPurulent pericarditisAplastic anemiaC. guilliermondiiInhibitory concentration rangePoor responseClinical isolatesAmphotericin BProlonged durationHigh MICsInitial misidentificationTherapyEnvironmental isolatesIsolatesControl strainMolecular analysisNeutropeniaPericarditisFungemiaAnemiaBMTFlucytosineAmB